Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cantargia AB
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Cash from Financing Activities
kr54.7m
CAGR 3-Years
-53%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash from Financing Activities
-kr308.4m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash from Financing Activities
-kr5.5m
CAGR 3-Years
55%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash from Financing Activities
-kr271m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
-19%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash from Financing Activities
-kr3.2B
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Cash from Financing Activities
kr14.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Cantargia AB's Cash from Financing Activities?
Cash from Financing Activities
54.7m SEK

Based on the financial report for Sep 30, 2024, Cantargia AB's Cash from Financing Activities amounts to 54.7m SEK.

What is Cantargia AB's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-11%

The average annual Cash from Financing Activities growth rates for Cantargia AB have been -53% over the past three years , -11% over the past five years .

Back to Top